Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Inclusion Criteria: 1. Age : 10\~60 2. Diagnosed with Dystrophic Epidermolysis Bullosa based on immunofluorescence test. 3. Bullous skin lesion sized over 10 cm\^2 4. Test negative for Serum β-HCG pregnancy test on screening, if the subject is fertile 5. A subject who is willing to follow the protocol and provide a informed consent on screening, given that the information with respect to the clinical trial is provided. Exclusion Criteria: 1. A subject with history of epidermoid carcinoma within a year from screening. 2. A subject who requires antibiotics due to bacterial infection on skin. 3. A subject who was dosed with oral steroid, over 0.5mg/kg a day for subjects under 18, or over 20mg in 2 weeks for subjects over 18, within 30 days prior to screening. 4. A subject treated with radiotherapy or immunosuppressants, within 30 days prior to screening. 5. A subject treated with steroids locally, within 30 days prior to screening. 6. A subject with 2-times the maximum-standardized value of ALT, AST, ALP, bilirubin, total protein 7. A subject with 2-times the maximum-standardized value of BUN, Creatinine 8. A subject with Albumin below 2.0 g/dL. 9. A subject with Hemoglobin below 6 g/dL (anemic). 10. A subject with allergic response to bovine derived protein and fibrin glue. 11. A subject administered with biologic agents or cell therapy, within 30 days prior to screening. 12. A subject administered with stem cell treatment by IV or subcutaneously to the target wound, prior to the trial 13. A subject who enrolled into another clinical trial, within 30 days prior to screening 14. A subject with serious disease that can affect on clinical trial. 15. A pregnant or breast-feeding subject. 16. A subject with history of drug abuse within 1 year of clinical significance 17. A subject who cannot proceed according to the protocol.